Index · Artikel · UK wants GSK's Avandia pulled as EU reviews safety

UK wants GSK's Avandia pulled as EU reviews safety

2010-09-05 4
   
Advertisement
résuméLONDON GlaxoSmithKline's diabetes drug Avandia should be pulled from sale because of concerns about heart risks, British drug regulators said on Monday ahead of a special European meeting on the drug's safety. The strong line from safety experts in t
Advertisement

UK wants GSK's Avandia pulled as EU reviews safety


LONDON GlaxoSmithKline's diabetes drug Avandia should be pulled from sale because of concerns about heart risks, British drug regulators said on Monday ahead of a special European meeting on the drug's safety.

The strong line from safety experts in the drugmaker's home market is a fresh blow to a medicine that was once Glaxo's second biggest seller but has become a liability since being linked to increased heart attack risk in 2007.

The Medicines and Healthcare products Regulatory Agency (MHRA) said it believed the risks of Avandia, known generically as rosiglitazone, outweighed its benefits and that "it no longer has a place on the UK market."

Spokesman Stephen Hallworth said the MHRA had put forward its position "robustly" to the European Medicines Agency (EMA) and would highlight its concerns again at a special meeting on the drug's future this week.

The EMA -- the decentralised European body responsible for licensing Avandia in 2000 -- will hold an extraordinary expert meeting on September 8 to review the drug's safety before finalizing its position at its next scheduled meeting on September 20 to 23.

London-based EMA said the additional meeting was necessary because of the complexity of the data being assessed.

The British Medical Journal (BMJ) and some leading doctors attacked the tardy response, calling for Avandia to be pulled off the market immediately and saying it should never have been licensed in the first place.

CALL FOR WITHDRAWAL IN JULY

British regulators' concerns about Avandia came to light following a BMJ investigation that found out the Commission on Human Medicines -- an independent working group advising UK ministers -- had recommended the withdrawal of Avandia in July.

A MHRA letter sent to doctors on July 26 merely advised them to "consider alternative treatments where appropriate."

Dr Deborah Cohen, who led the BMJ investigation, said letter was not clear enough, and the MHRA should have informed doctors of the commission's full opinion.

"Medicine is all about benefits versus risks," she said in a telephone interview. "And if a group of experts in drug safety believes the risks outweigh the benefits, that's an important message that would inform doctors when they're prescribing."

The BMJ's editor, Dr Fiona Godlee, told Reuters: "The time has now come for this drug to be withdrawn from the market."

Avandia used to be Glaxo's second-biggest drug, selling $3 billion in 2006 until health concerns emerged. Its sales plunged to $1.2 billion in 2009, or some 2.7 percent of group sales, as many doctors switched to Takeda's rival drug Actos.

John Yudkin of University College London said the problems with Avandia, which will also be the subject of a BBC Panorama programme on Monday, highlighted clear shortfalls in the regulatory system.

"Ten years after the release of rosiglitazone, we still cannot accurately quantify the harm to which we were exposing our patients," he said. "If the regulatory bodies do not insist on clear evidence of greater benefit than harm, they are failing in their basic purpose."

FDA DECISION

In the United States, health advisers recommended to regulators on July 14 that Avandia should be allowed to stay on the market but with additional warnings.

The Food and Drug Administration is expected to make a final decision on Avandia later this month and the agency usually follows recommendations from its advisory committees.

Glaxo said an extensive research programme showed Avandia was safe and effective when used appropriately according to its labeling.

The drugmaker has faced a slew of lawsuits in the U.S. but tried to put the issue behind it in July by taking a record legal charge of 1.57 billion pounds ($2.4 billion), partly to settle the bulk of the Avandia claims.

Britain's Department of Health said in a statement it was aware of concerns about Avandia, but advised patients not to stop taking their medication without talking to a doctor.

"MHRA has issued guidance to all healthcare professionals with clear warnings about the associated risks for some patients," it said. "Ministers have not been asked to make any decisions about the license of Avandia in the UK."

(Editing by Karen Foster)

TOP

  • Day/
  • Week/
  • Original/
  • Recommand

Updated

  • Glaxo says U.S. panel recommends Cervarix vaccine

    Glaxo says U.S. panel recommends Cervarix vaccine
    WASHINGTON A U.S. advisory panel has recommended the use of GlaxoSmithKline PLC's Cervarix vaccine to prevent cervical cancer in girls and young women, the company said on Wednesday. The Centers for Disease Control and Prevention's Advisory Committee
  • Low Dose PremPro oder Activella - was ist der Unterschied?

    Kann jemand bitte die primäre Unterschied in PremPro 0,3 mg / 1,5 mg vs. Activella 0,5 mg / 0,1 mg klären? Ich war auf der niedrigen Dosis PremPro seit vielen Jahren und blieb ein Jahr lang als mein OB-GYN im Ruhestand. Hatte Nachtschweiß, Schlafstör
  • Can u Prevacid mit Anfalls Meds Phenytek 300mg, myla & Dilantin 50mgPFIZ nehmen?

    I`am Reaktion haveing ​​zu med & `t takeing Anfalls med stoppen. für ca. 6 wks haben schlecht hatte suchen Orte auf dem Rücken ----schneiden---- In Antwort auf Marjorie ... bei 2010-11-01 08.55 Ich würde sie etwa zwei Stunden auseinander nehmen, so d
  • Morgen lesen: Gesundheitsreform ist nicht vorbei

    Morgen lesen: Gesundheitsreform ist nicht vorbei
    Highlights der wichtigen und interessanten aus der Welt der Gesundheitsversorgung: Gesundheitsreform nicht über: Versicherung Lobbyisten versuchen, Regelungen zu gestalten , die "unvernünftig" Prämie erhöht und verlangen Versicherer definieren R
  • Nur Celexa (für Angst) gestartet?

    Innerhalb von 3 Stunden nach der ersten Dosis, hatte einen massiven Panikattacke - zunächst dachte, es wäre eine negative Reaktion! Sobald das geklärt, ging ich schlafen. Ich wachte heute das Gefühl absolut wunderbar. Ich bin nur gespannt, ob jemand
  • Kann eine gemeinsame STD Ursache Prostatakrebs?

    Kann eine gemeinsame STD Ursache Prostatakrebs?
    Trichomonas vaginalis, der Parasit, der Trichomoniasis verursacht. Credit: University of Alaska, Anchorage Prostatakrebs ist die zweithäufigste Krebsart bei Männern in den Vereinigten Staaten, nach der American Cancer Society, und fast 30.000 amerika
  • Einfach ungesättigte Vs mehrfach ungesättigte Fette: Was ist der Unterschied?

    Einfach ungesättigte Vs mehrfach ungesättigte Fette: Was ist der Unterschied?
    Es gibt zwei Hauptkategorien von Fett: gesättigte und ungesättigte Fette. Gesättigte Fette können sich negativ auf bestimmte Aspekte Ihres Lipidprofil beeinflussen und das Risiko für Herz-Kreislauf-Erkrankungen erhöhen können - vor allem, wenn Sie ko
  • Einführung in die Viniyoga

    Einführung in die Viniyoga
    Viniyoga (das ist nicht dasselbe wie Vinyasa Yoga!) Ist über die Anpassung. Es basiert auf dem Guru / Schüler-Modell basiert, in dem ein erfahrener Lehrer individuell mit jedem Schüler arbeitet, eine personalisierte Yoga-Programm für sie machen basie
  • 10 gesundheitlichen Vorteile von Mulberries

    10 gesundheitlichen Vorteile von Mulberries
    10 Nutzen für die Gesundheit von mulberries plus so viel mehr! Mulberries sind eine leckere und nahrhafte Gesundheit Lebensmittel , die Sie wachsen wild oder Kauf bei Ihrem örtlichen Bauernmarkt oder im Bioladen zu finden. Sie sollten zu Ihrer Heilun
  • Deutschland hat einen offiziellen Third Gender

    Deutschland hat einen offiziellen Third Gender
    Ein neues Gesetz in Deutschland entsteht ein drittes Geschlecht Kategorie auf Geburtsurkunden. Es könnte wie eine offensichtliche Lösung einiger Probleme von Intersex scheinen: Wenn manche Babys mit Körper geboren werden, die weder eindeutig männlich